Chinmay Jani, Clinical Fellow of Hematology and Oncology at the University of Miami, shared a post on X:
“SCLC no longer left behind!
The FOMO is slowly fading as novel therapies emerge across lines:
- Consolidation durvalumab is now standard for LS-SCLC.
- DLL3 BiTEs -Tarlatamab and ADCs (TROP2, SEZ6, B7-H3) in various lines.
Fantastic panel led by Lauren Averett Byers!”
More posts featuring Chinmay Jani.
